Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib

Clin Transl Sci. 2016 Apr;9(2):63-73. doi: 10.1111/cts.12388. Epub 2016 Mar 1.

Authors

P Selaru¹, Y Tang¹, B Huang², A Polli³, K D Wilner¹, E Donnelly⁴, D P Cohen¹

Affiliations

¹ Pfizer Oncology, La Jolla, California, USA.
² Pfizer Oncology, Groton, Connecticut, USA.
³ Pfizer Oncology, Milan, Italy.
⁴ Pfizer Oncology, Cambridge, Massachusetts, USA.

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use
Crizotinib
Drug Approval
Drug Discovery*
Humans
Neoplasms / drug therapy*
Neoplasms / genetics
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Pyrazoles
Pyridines
Crizotinib